Squarepoint’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.88M Buy
14,800
+7,500
+103% +$1.55M ﹤0.01% 2040
2026
Q1
$1.64M Sell
7,300
-6,300
-46% -$1.57M ﹤0.01% 2356
2025
Q4
$3.28M Buy
+13,600
New +$3.48M ﹤0.01% 1730
2025
Q3
Sell
-1,600
Closed -$413K 4896
2025
Q2
$413K Buy
+1,600
New +$382K ﹤0.01% 3431
2024
Q4
Sell
-2,900
Closed -$708K 5423
2024
Q3
$708K Buy
2,900
+900
+45% +$201K ﹤0.01% 2860
2024
Q2
$383K Buy
+2,000
New +$406K ﹤0.01% 3270
2024
Q1
Sell
-6,100
Closed -$1.05M 4521
2023
Q4
$1.05M Sell
6,100
-4,600
-43% -$707K ﹤0.01% 2487
2023
Q3
$1.58M Buy
+10,700
New +$1.93M ﹤0.01% 1999

Other funds holding RMD

Squarepoint's RMD Position: Q2 2026 in Review

Squarepoint increased its ResMed (RMD) stake by 553% in Q2 2026, buying an estimated $4.44M and bringing the position to 25,280 shares worth $4.93M. The position accounts for 0.01% of the portfolio, ranked #1610.

Squarepoint first reported a position in RMD in Q4 2015 and has held it in 31 quarters since. The position peaked at $141M in Q2 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Squarepoint held 25,280 shares of ResMed worth $4.93M as of Q2 2026.
  • Squarepoint bought 21,408 ResMed shares in Q2 2026, an estimated $4.44M.
  • ResMed made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1610 holding.
  • Squarepoint first reported a position in ResMed in Q4 2015 and has held it in 31 quarters since.
  • Squarepoint's ResMed position peaked at $141M in Q2 2025.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.